Degli Esposti Luca, Piccinni Carlo, Sangiorgi Diego, Fagiolini Andrea, Buda Stefano
CliCon Srl, Health, Economics and Outcomes Research, Via Salara, 36, 48100, Ravenna, Italy.
Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Clin Drug Investig. 2015 Nov;35(11):735-42. doi: 10.1007/s40261-015-0332-4.
This study aimed to describe the prescription pattern of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) in an Italian setting, focusing on therapy duration, switching and adherence.
Historic cohort study, based on administrative databases of three Italian local health-units, was conducted. Patients with a prescription of antidepressants (ADs) in 2009 were enrolled and grouped into: (1) naïve, (2) already in treatment with the same drug and (3) already in treatment with a different drug. Therapy duration, switching and adherence [as medication possession ratio-(MPR)] were evaluated. A logistic regression model was performed to identify predictors of adherence.
There were 88,755 subjects recruited: 37 % naïve, 58 % already in treatment with the same drug and 4 % with different drug. A treatment duration of ≤3 months was found in 41 % of naïve patients, whereas the majority of patients already in treatment had a duration of ≥6 months. Switches occurred in 0.7 % of the whole cohort and mostly occurred between two different SSRIs. The 63 % of naïve patients had a low adherence (MPR < 60 %), whereas a good adherence (MPR ≥ 80 %) was found in 58 % of patients already in treatment with the same drug and in 39 % of those already in treatment with different drug. Predictors of adherence were: female gender, increasing comorbidity and pain absence. All ADs, except for fluoxetine and venlafaxine, showed a better adherence than paroxetine.
Notwithstanding the difficulty to associate the AD prescription to the specific diagnosis of depression, this study highlighted a short duration and a low adherence of AD therapies, especially at the initiation of treatment. Physicians should carefully balance the need to prescribe these drugs, considering the great likelihood of a short duration of treatment and a very low level of adherence.
本研究旨在描述意大利环境下选择性5-羟色胺再摄取抑制剂(SSRIs)和5-羟色胺及去甲肾上腺素再摄取抑制剂(SNRIs)的处方模式,重点关注治疗持续时间、换药情况和依从性。
基于意大利三个地方卫生单位的行政数据库进行历史性队列研究。纳入2009年开具抗抑郁药(ADs)处方的患者,并分为:(1)初治患者,(2)正在使用同一药物治疗的患者,以及(3)正在使用不同药物治疗的患者。评估治疗持续时间、换药情况和依从性[以药物持有率(MPR)表示]。进行逻辑回归模型以确定依从性的预测因素。
共招募了88755名受试者:37%为初治患者,58%正在使用同一药物治疗,4%正在使用不同药物治疗。41%的初治患者治疗持续时间≤3个月,而大多数正在接受治疗的患者治疗持续时间≥6个月。整个队列中0.7%的患者发生了换药,且大多发生在两种不同的SSRIs之间。63%的初治患者依从性低(MPR<60%),而正在使用同一药物治疗的患者中58%以及正在使用不同药物治疗的患者中39%具有良好的依从性(MPR≥80%)。依从性的预测因素为:女性、合并症增加和无疼痛。除氟西汀和文拉法辛外,所有ADs的依从性均优于帕罗西汀。
尽管难以将AD处方与抑郁症的具体诊断相关联,但本研究突出了AD治疗的持续时间短和依从性低的问题,尤其是在治疗开始时。考虑到治疗持续时间短和依从性极低的极大可能性,医生在开具这些药物时应仔细权衡必要性。